A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors

Publications
Written By Martin Lehr
Martin Lehr
Previous

CT-202: a Dual pH-dependent Nectin-4xCD3 Bispecific T Cell Engager
Next

Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3